If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Estrogens are involved in libido (sex drive) in both women and men. In women, estrogen levels are elevated during the periovulatory period of the menstrual cycle, which is associated with increased sexual motivation. Libido is dependent on androgen levels only in the presence of estrogens. Without estrogens, free testosterone level actually decreases sexual desire. Sexual desire in women who have hypoactive sexual desire disorder can be restored by administration of estrogen (using oral contraceptive). Estrogens are required for female mammals to engage in lordosis behavior during estrus. This behavior is required for sexual receptivity in these mammals and is regulated by the ventromedial nucleus of the hypothalamus.
=== Affinity chromatography === Affinity chromatography emerged in the 1950s as a rarely used method used to purify enzymes; it has since seen mainstream use and is the oldest among chemoproteomic approaches. Affinity chromatography is performed following one of two basic formats: ligand immobilization or target immobilization. Under the ligand immobilization format, a ligand of interest - often a drug lead - is immobilized within a chromatography column and acts as the stationary phase. A complex sample consisting of many proteins, such as a cell lysate, is passed through the column and the target of interest binds to the immobilized ligand while other sample components pass through the column unretained. Under the target immobilization format, a target of interest - often a disease-relevant protein - is immobilized within a chromatography column and acts as the stationary phase. Pooled compound libraries are then passed through the column in an application buffer, ligands are retained through binding interactions with the stationary phase, and other compounds pass through the column unretained. In both cases, retained analytes can be eluted from the column and identified using mass spectrometry. A table of elution strategies is provided below.
== Treatment == Antivenom therapy is the current standard treatment for snake envenoming. In China, the Bungarus multicinctus monovalent antivenom (BMMAV) is produced and, in Taiwan the Neuro bivalent antivenom (NBAV). Both antivenoms are immunoreactive to the neurotoxins found in the venom, including the α-BTX, which neutralize the venom lethality. BMMAV is specifically designed to neutralize the venom of the Bungarus multicinctus, therefore being more efficacious compared to NBAV. On the other hand, NBAV targets the venom from multiple species of snakes that produce neurotoxic effects, including the Bungarus multicinctus. The use of BMMAV or NBAV might differ based on availability, regional protocols and the specific venomous snake that is present in the area.
Sources: en.wikipedia.org
The term was coined from the Greek roots schizein and phrēn, "to split" and "mind", in reference to a "splitting of mental functions" seen in schizophrenia, not a splitting of the personality. A split or multiple personality is dissociative identity disorder.
=== Fertility aid === One of the most damaged areas of the body following chemotherapy is typically the uterus. Following uterine damage due to cancer treatment, follicle damage makes it difficult for individuals to get pregnant even if viable ova are present. With bone marrow stem cell transplants, chemotherapy patients have been able to increase their fertility as follicle damage is repaired. As follicles are necessary for ovum attachment to the endometrium, it is important for these areas to be repaired in order to increase fertility. For individuals who have sustained egg and follicle damage, IVF has been found to be more effective following bone marrow stem cell transplantation. One human clinical case has shown improvements of uterine lining thickness and overall endometrium repair following bone marrow stem cell transplantation. This repair allowed for the patient to successfully become pregnant and carry to term. Additional repairs following bone marrow stem cell transplant to the endometrium include increased vascularity and iron levels, with egg implantation clustering around areas with high blood flow.
The median lethal dose (LD50) of a venom is the dose required to kill half the members of a tested population after a specified test duration. A lower LD50 number indicates increased toxicity. There are four methods for administering the LD50 test: Subcutaneous: Venom is injected into the fatty layer beneath the skin. Intravenous: Venom is injected directly into a vein. Intramuscular: Venom is injected into a muscle. Intraperitoneal: Venom is injected into the abdominal cavity. The most commonly tested methods are subcutaneous and intravenous injections, using mice. Subcutaneous is the most applicable to actual bites: Only large Bitis or extremely large Bothrops or Crotalus specimens are able to deliver a bite that is truly intramuscular, and intravenous injections are extremely rare in actual bites. Mixing dry venom with 0.1% bovine serum albumin in saline gives more consistent test results than mixing with saline alone. Wayne C Hodgson et al. stated in 2002: "Historically, the lethality of snake venoms has been based on murine LD50 studies. Due to ethical reasons, these studies are being superseded by in vitro studies. Instead, the time taken to produce 90% inhibition of nerve-mediated twitches (i.e. t90) in skeletal muscle preparations can be determined".
== Work == Development of dedicated machinery for insulin extraction and purification at the Zoophysiology Laboratory workshop. Design and implementation of early insulin delivery technologies (the "Novo Syringe" for self-injection). Co-development of Insulin Novo, marketed by Novo Terapeutisk in the mid-1920s.
Sources: en.wikipedia.org
== Presentation == Most individuals diagnosed with LECT2 amyloidosis in the United States (88%) are of Mexican descent and reside in Southwest region of the United States (New Mexico, Arizona, far Western Texas). Other groups with higher incidence rates of the disorder include First Nation Peoples in Canada, Punjabis, South Asians, Sudanese, Native Americans, and Egyptians. In Egyptians, for example, LECT2 is second most common cause of renal amyloidosis, accounting for nearly 31% of all cases. LECT2 amyloidosis (ALECT2) is generally diagnosed in individuals between the ages 40 and 90, with a mean age of 67 years old. The disorder commonly presents with renal disease that in general is advanced or at an end stage. Associated signs and symptoms of their renal disease may include fatigue, dehydration, blood in urine, and/or other evidence for the presence of the nephrotic syndrome or renal failure. Further studies may find that these individuals have histological or other evidence of LECT2 amyloid deposition in the liver, lung, spleen, kidney, and/or adrenal glands but nonetheless they rarely show any symptoms or signs attributable to dysfunction in these organs. Unlike many other forms of systemic amyloidosis, LECT2 deposition has not been reported to be deposited in the myocardium or brain of affected individuals. Thus, LECT2 amyloidosis, while classified as a form of systemic amyloidosis, almost exclusively manifests clinically as renal amyloidosis. No familial link has been found in the disorder although there have been several cases described among siblings.
==== Mechanisms of plasticity ==== To understand mechanisms of activity-dependent plasticity, Sur’s lab used microarray analyses of classic visual plasticity paradigms (dark-rearing and monocular deprivation during the critical period) to discover gene expression changes and microRNAs associated with cortical plasticity. They demonstrated rules of plasticity and the role of specific molecules in implementing these rules. His lab showed that neuronal plasticity is implemented by locally coordinated potentiation and depression of spines, which involves AMPA receptor redistribution via targeted expression of Arc. Together with large-scale synaptic dynamics of V1 neurons during normal development, these findings have demonstrated a fundamental principle, that Hebbian strengthening of coactive synapses and heterosynaptic weakening of adjacent synapses cooperatively mediate neuron-wide plasticity.
== Toxicity == Several typical mechanisms underlying graphene (oxide) nanomaterial's toxicity have been revealed, for instance, physical destruction, oxidative stress, DNA damage, inflammatory response, apoptosis, autophagy, and necrosis. In these mechanisms, toll-like receptors (TLR), transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α) dependent-pathways are involved in the signalling pathway network, and oxidative stress plays a crucial role in these pathways. Many experiments have shown that graphene (oxide) nanomaterials have toxic side effects in many biological applications, but more in-depth study of toxicity mechanisms is needed. According to the USA FDA, graphene, graphene oxide, and reduced graphene oxide elicit toxic effects both in vitro and in vivo. Graphene-family nanomaterials (GFN) are not approved by the USA FDA for human consumption.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.